Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the ...

A multicenter collaboration has identified a potential new treatment for an aggressive sarcoma arising in the nerves. The ...

Pfizer Inc. today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of BRAFTOVI® (encorafenib) in combination with cetuximab ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

Investigative therapies to treat moderate to severe plaque psoriasis in clinical trials include several orally administered ...

Botox has long been touted as the “secret of youth.” However, everyone knows that it changes facial features (and not always ...

A Bay Area biotech firm is laying off 75% of its staff following a flopped clinical trial. Allakos, based in San Carlos, ...

Vertex has gained the FDA's approval for its nonaddictive pain med Journavx, which becomes the first significant innovation ...

If the drug is approved by the US Food and Drug Administration for the treatment of acute pain in January as expected, the ...

Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) shares are trading higher Friday following two major developments that strengthen ...

The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...